Cargando…

Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in Canada

The prognosis for extensive-stage small cell lung cancer (ES-SCLC) is poor. Real-world evidence can highlight the unmet clinical need within this population. We conducted a population-based cohort study of ES-SCLC patients diagnosed in a large Canadian province (2010–2018) using electronic medical r...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Sullivan, Dylan E., Cheung, Winson Y., Syed, Iqra A., Moldaver, Daniel, Shanahan, Mary Kate, Bebb, D. Gwyn, Sit, Christina, Brenner, Darren R., Boyne, Devon J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395392/
https://www.ncbi.nlm.nih.gov/pubmed/34436036
http://dx.doi.org/10.3390/curroncol28040270
_version_ 1783744161148567552
author O’Sullivan, Dylan E.
Cheung, Winson Y.
Syed, Iqra A.
Moldaver, Daniel
Shanahan, Mary Kate
Bebb, D. Gwyn
Sit, Christina
Brenner, Darren R.
Boyne, Devon J.
author_facet O’Sullivan, Dylan E.
Cheung, Winson Y.
Syed, Iqra A.
Moldaver, Daniel
Shanahan, Mary Kate
Bebb, D. Gwyn
Sit, Christina
Brenner, Darren R.
Boyne, Devon J.
author_sort O’Sullivan, Dylan E.
collection PubMed
description The prognosis for extensive-stage small cell lung cancer (ES-SCLC) is poor. Real-world evidence can highlight the unmet clinical need within this population. We conducted a population-based cohort study of ES-SCLC patients diagnosed in a large Canadian province (2010–2018) using electronic medical records and administrative claims data. In all, 1941 ES-SCLC patients were included, of which 476 (25%) were recurrent cases. Median age at diagnosis was 70 years (range: 39–94) and 50.2% were men. Of the 1941 ES-SCLC patients, 29.5% received chemotherapy and radiotherapy, 17.0% chemotherapy alone, 8.7% radiotherapy alone, and 44.8% received best supportive care. Chemotherapy was initiated by 46.5%, 8.5%, and 1.4% of first-, second-, and third-line patients, with lower uptake for recurrent cases. Median survival from first-, second-, and third-line chemotherapy was 7.82 months (95% CI: 7.50–8.22), 5.72 months (95% CI: 4.90–6.87), and 3.83 months (95% CI: 2.99–4.60). Among patients who received first-line therapy, the 2-year and 5-year survival was 7.3% (95% CI: 5.7–9.2) and 2.9% (95% CI: 1.8–4.5). In conclusion, initiation of first-line treatment in ES-SCLC was low with significant attrition in subsequent lines. These results underscore the need for effective front-line treatments and highlight the potential for novel therapies to improve patient outcomes.
format Online
Article
Text
id pubmed-8395392
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83953922021-08-28 Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in Canada O’Sullivan, Dylan E. Cheung, Winson Y. Syed, Iqra A. Moldaver, Daniel Shanahan, Mary Kate Bebb, D. Gwyn Sit, Christina Brenner, Darren R. Boyne, Devon J. Curr Oncol Article The prognosis for extensive-stage small cell lung cancer (ES-SCLC) is poor. Real-world evidence can highlight the unmet clinical need within this population. We conducted a population-based cohort study of ES-SCLC patients diagnosed in a large Canadian province (2010–2018) using electronic medical records and administrative claims data. In all, 1941 ES-SCLC patients were included, of which 476 (25%) were recurrent cases. Median age at diagnosis was 70 years (range: 39–94) and 50.2% were men. Of the 1941 ES-SCLC patients, 29.5% received chemotherapy and radiotherapy, 17.0% chemotherapy alone, 8.7% radiotherapy alone, and 44.8% received best supportive care. Chemotherapy was initiated by 46.5%, 8.5%, and 1.4% of first-, second-, and third-line patients, with lower uptake for recurrent cases. Median survival from first-, second-, and third-line chemotherapy was 7.82 months (95% CI: 7.50–8.22), 5.72 months (95% CI: 4.90–6.87), and 3.83 months (95% CI: 2.99–4.60). Among patients who received first-line therapy, the 2-year and 5-year survival was 7.3% (95% CI: 5.7–9.2) and 2.9% (95% CI: 1.8–4.5). In conclusion, initiation of first-line treatment in ES-SCLC was low with significant attrition in subsequent lines. These results underscore the need for effective front-line treatments and highlight the potential for novel therapies to improve patient outcomes. MDPI 2021-08-13 /pmc/articles/PMC8395392/ /pubmed/34436036 http://dx.doi.org/10.3390/curroncol28040270 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
O’Sullivan, Dylan E.
Cheung, Winson Y.
Syed, Iqra A.
Moldaver, Daniel
Shanahan, Mary Kate
Bebb, D. Gwyn
Sit, Christina
Brenner, Darren R.
Boyne, Devon J.
Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in Canada
title Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in Canada
title_full Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in Canada
title_fullStr Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in Canada
title_full_unstemmed Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in Canada
title_short Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in Canada
title_sort real-world treatment patterns, clinical outcomes, and health care resource utilization in extensive-stage small cell lung cancer in canada
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395392/
https://www.ncbi.nlm.nih.gov/pubmed/34436036
http://dx.doi.org/10.3390/curroncol28040270
work_keys_str_mv AT osullivandylane realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinextensivestagesmallcelllungcancerincanada
AT cheungwinsony realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinextensivestagesmallcelllungcancerincanada
AT syediqraa realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinextensivestagesmallcelllungcancerincanada
AT moldaverdaniel realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinextensivestagesmallcelllungcancerincanada
AT shanahanmarykate realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinextensivestagesmallcelllungcancerincanada
AT bebbdgwyn realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinextensivestagesmallcelllungcancerincanada
AT sitchristina realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinextensivestagesmallcelllungcancerincanada
AT brennerdarrenr realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinextensivestagesmallcelllungcancerincanada
AT boynedevonj realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinextensivestagesmallcelllungcancerincanada